Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
Type 2 diabetes is treated in a stepwise manner, progressing from diet and physical activity to oral antidiabetic agents and insulin. The oral agent pioglitazone is licensed for use with insulin when metformin is contraindicated or not tolerated. This systematic review and meta-analysis investigates...
Main Authors: | Christine Clar, Pamela Royle, Norman Waugh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-07-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2701605?pdf=render |
Similar Items
-
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
by: Sharma Pawana, et al.
Published: (2010-12-01) -
Self-monitoring of blood glucose in type 2 diabetes: systematic review
by: C Clar, et al.
Published: (2010-03-01) -
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
by: Toshikazu Yamanouchi
Published: (2010-03-01) -
Systematic reviews of epidemiology in diabetes: finding the evidence
by: Waugh Norman, et al.
Published: (2005-01-01) -
Comparison of Basal Insulin versus Pioglitazone Added to Oral Agents Therapy for Poor Controlled of Type 2 Diabetes
by: Li-Chen Chang Chien, et al.
Published: (2011)